 |
16 Diseases |  |
0 Trials |
|
0 Trials |  |
23 News |  |
- | Avastin (bevacizumab) / Roche
Preclinical, Journal: Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI. (Pubmed Central) - Oct 25, 2020
Our results provide direct evidence that CCL2 expression can increase the resistance to bevacizumab, which can be assessed noninvasively with the DSC-MR imaging technique. This study shows that the suppression of CCL2 can play an important role in increasing the efficacy of anti-angiogenic treatment in GBM by inhibiting the recruitment of CCL2-dependent macrophages.
- | olaptesed pegol (NOX-A12) / Noxxon, emapticap pegol (NOX E36) / Noxxon
Journal: CCL2/MCP-1 and CXCL12/SDF-1 BLOCKADE BY L-aptamers IMPROVE PANCREATIC ISLET ENGRAFTMENT AND SURVIVAL IN MOUSE. (Pubmed Central) - Sep 13, 2020
Additionally, both L-aptamers significantly attenuated diabetes progression in the MLD-STZ model. In conclusion, CCL2/MCP-1 and CXCL12/SDF-1 blockade by L-aptamers is an efficient strategy to improve islet engraftment and survival.
- |||| emapticap pegol (NOX E36) / TME Pharma
Trial completion: NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria (clinicaltrials.gov) - Feb 20, 2014
P2a, N=76, Completed, Sponsor: NOXXON Pharma AG
In conclusion, CCL2/MCP-1 and CXCL12/SDF-1 blockade by L-aptamers is an efficient strategy to improve islet engraftment and survival. Active, not recruiting --> Completed
- emapticap pegol (NOX E36) / TME Pharma
Trial completion: NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Feb 11, 2013
P1/2, N=47, Completed, Sponsor: Noxxon Pharma AG
Active, not recruiting --> Completed Active, not recruiting --> Completed
- emapticap pegol (NOX E36) / TME Pharma
Trial completion: A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36 (clinicaltrials.gov) - Oct 17, 2012
P1, N=32, Completed, Sponsor: Noxxon Pharma AG
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| emapticap pegol (NOX E36) / TME Pharma
New P2a trial: NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria (clinicaltrials.gov) - Mar 6, 2012
P2a, N=76, Completed, Sponsor: NOXXON Pharma AG